Cancer immunotherapy enters a transformative phase with novel strategies targeting tumor immune evasion. Recent studies reveal mechanisms by which colorectal cancer stem cells evade immune responses via IL-6 signaling, and innovative CAR macrophages generated through mRNA delivery show promise in reducing lung metastasis. Additionally, newly identified immune checkpoint targets like TIGIT offer fresh pathways, while combined alpha therapy with BET inhibitors shows synergistic efficacy in prostate cancer. These developments could broaden treatment options and improve patient outcomes across tumor types.